


# Medical Pharmacology




***Robiul*** Islam, PhD  
College of Medicine and  
Dentistry



*Celebrating*  
**50**  
YEARS  
1970 - 2020



# Genitourinary Drugs



Rang & Dale's  
Pharmacology  
10<sup>th</sup> ed 2020  
Chap 29, 35

## **COMMONWEALTH OF AUSTRALIA**

Copyright Regulations 1969

### **WARNING**

This material has been reproduced and communicated to you by or on behalf of James Cook University in accordance with section 113P of the Copyright Act 1968 (Act).

The material in this communication may be subject to copyright under the Act. Any further reproduction or communication of this material by you may be the subject of copyright protection under the Act.

**Do not remove this notice**

# Genitourinary Drugs

<b>THERAPEUTIC CLASS</b>	<b>SUB CLASS</b>	<b>EXEMPLAR</b>
<b>Drugs for sexual dysfunction</b>	Phosphodiesterase 5 inhibitors	sildenafil
<b>Drugs for urinary incontinence</b>	Anticholinergics (genitourinary)	oxybutynin
	desmopressin	
<b>Drugs for benign prostatic hyperplasia and prostatitis</b>	Selective alpha-blockers (genitourinary)	tamsulosin
	5-Alpha-reductase inhibitors	dutasteride

# Drugs for sexual dysfunction - PDE 5 inhibitors

## Exemplar

- sildenafil, tadalafil and avanafil

## Mechanism of action


- penile erection results from dilation of the corpus cavernosa smooth muscle and increased blood flow
- dilation due to nitric oxide (NO), which stimulates soluble GC to synthesise cGMP, in turn activates PKG, leads to decreased cytosolic Ca<sup>2+</sup> and smooth muscle relaxation
- Phosphodiesterase-5 normally breaks down cGMP

## Adverse effects / Precautions



- headache, flushing, priapism, dizziness, vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION)
- contraindicated with nitric oxide donors (**nitrates**)
- precautions in CV disease

# Drugs for sexual (**erectile**) dysfunction

## - PDE 5 inhibitors




# Drugs for sexual dysfunction - PDE 5 inhibitors




# Urinary incontinence

Chart i: Projected prevalence of incontinence in Australians aged 15 years and over, 2010 to 2030



Source: Hawthorne (2006), Access Economics Demographic Model (AEDM), Department of Health and Ageing, Ageing and aged care data warehouse<sup>1</sup>, Productivity Commission (PC) (2010).

Figure 3.16.1: Prevalence of severe incontinence, by age and sex, 2012



Source: AIHW analysis of the 2012 Survey of Disability, Ageing and Carers (ABS 2013).



# HRM

# Bladder Nerves

## Somatic

- Pudendal Nerves (S2, S3, S4)
- External urethral sphincter



## Sympathetic

- Hypogastric Nerves (L1, L2, L3)
- Bladder wall relaxation, internal sphincter contraction

## Parasympathetic

- Pelvic Nerves (S2, S3, S4)
- Bladder wall contraction, internal sphincter relaxation

- Parasympathetic Supply – Bladder detrusor muscle contraction and Internal sphincter relaxation
  - Facilitate emptying
- Sympathetic Nerves – Inhibition and relaxation of the detrusor – via  $\beta_3$  receptors; Contraction of internal sphincter – via  $\alpha_1$  receptor
  - Facilitate storage
- Somatic Nerves – Control the external sphincter – Nicotinic receptor



# Drugs for urinary incontinence

## - Anticholinergics

### Exemplar

- Oxybutynin, solifenacin

### Indications


- overactive bladder, urge incontinence
  - symptoms include urgency, frequency, nocturia
  - caused by spontaneous detrusor contractions

### Mechanism of action

- selectively (?) inhibits M3 receptors on detrusor smooth muscle


### Adverse effects / Precautions

- dry mouth, constipation, blurred vision
- contraindicated in glaucoma, caution in cognitive disorders, use with other anticholinergics



# Anticholinergics

# Genitourinary Drugs




# Drugs for urinary incontinence - Desmopressin

## Indications

- nocturnal enuresis in children
- nocturnal polyuria in adults
- also diabetes insipidus due to ADH deficiency

## Mechanism of action

- ADH analogue
- acts at V2 (?) receptors in distal tubules and collecting ducts
- increases expression of aquaporins in the luminal membrane thus increases water reuptake
- Adverse effects / Precautions / other
- Hyponatraemia; contraindicated in HF, concurrent diuretic treatment
- Intranasal, oral, sublingual admin



# Drugs for urinary incontinence - Desmopressin

## Indications



- nocturnal enuresis
- nocturnal polyuria
- also diabetes insipidus due to ADH deficiency

## Mechanism of action

- ADH analogue
- acts at V2 (?) receptors
- increases expression of aquaporin-2 water channels

## Adverse effects / Precautions / Contraindications

- Hyponatraemia; contraindicated in HF, concurrent diuretic treatment
- Intranasal, oral, sublingual administration




collecting ducts

apical membrane thus increases

# Desmopressin

# Genitourinary Drugs





# Bladder outlet obstruction (BOO)

- major cause **benign prostatic hyperplasia** (BPH)
- affects >90% males by 80y (40% symptomatic)

## BOO is due to :

- compression by enlarged prostate
- contraction by bladder smooth muscle
- voiding & storage symptoms
- prostate hyperplasia mainly due to the dihydrotestosterone (DHT)
  - synthesised from testosterone by 5-alpha reductase
  - DHT forms complex with nuclear androgen receptors, which bind to DNA response elements to activate transcription, resulting in prostate cell growth and proliferation



# Benign Prostatic Hyperplasia (BPH)


- Symptoms (Prostatism)
  - Weak urine stream prolonged voiding
  - Hesitancy in initiating voiding
  - A “stop and start” stream
  - Having to strain to urinate
  - Post-voiding dribbling
  - Sensation of incomplete emptying
  - Needing to urinate frequently
  - Feelings of urgency
  - Night-time urination
  - Overflow incontinence
  - Dysuria (painful urination)



# Drugs for benign prostatic hyperplasia (BPH) – 5-alpha-reductase inhibitors

## Exemplar

- dutasteride, finasteride




## Mechanism of action

- 5-alpha-reductase inhibitors block conversion of testosterone to DHT, reducing hyperplasia and associated symptoms
- **slow onset of action (months, compliance is important)**

## Adverse effects / Precautions

- reduced libido (5%), impotence (5%)
- breast tenderness
- contraindicated in those without a prostate

**F** finasteride



# Drugs for benign prostatic hyperplasia

## - Selective alpha-blockers (genitourinary)

### Exemplar


- Tamsulosin, silodosin, prazosin

### Mechanism of action

- Prostate and bladder neck smooth muscle tone is normally maintained by NE at **alpha-1A** adrenoceptors
- inhibition relaxes smooth muscle, improving urine flow; also inhibits prostate smooth muscle hypertrophy hyperplasia
- Tamsulosin is 10-fold selective for  $\alpha_1A$ -receptors compared with  $\alpha_1B$

### Adverse effects

- orthostatic hypotension, dizziness, retrograde ejaculation, **impotence**





# The pharmacology of $\alpha_1$ -adrenoceptor subtypes

James R Docherty <sup>1</sup>

Affiliations + expand

PMID: 31067439 DOI: [10.1016/j.ejphar.2019.04.047](https://doi.org/10.1016/j.ejphar.2019.04.047)

## Abstract

This review examines the functions of  $\alpha_1$ -adrenoceptor subtypes, particularly in terms of contraction of smooth muscle. There are 3 subtypes of  $\alpha_1$ -adrenoceptor,  $\alpha_{1A}$ -,  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptors. Evidence is presented that the postulated  $\alpha_{1L}$ -adrenoceptor is simply the native  $\alpha_{1A}$ -adrenoceptor at which prazosin has low potency. In most isolated tissue studies, smooth muscle contractions to exogenous agonists are mediated particularly by  $\alpha_{1A}$ -, with a lesser role for  $\alpha_{1D}$ -adrenoceptors, but  $\alpha_{1B}$ -adrenoceptors are clearly involved in contractions of some tissues, for example, the spleen. However, nerve-evoked responses are the most crucial physiologically, so that these studies of exogenous agonists may overestimate the importance of  $\alpha_{1A}$ -adrenoceptors. **The major  $\alpha_1$ -adrenoceptors involved in blood pressure control by sympathetic nerves are the  $\alpha_{1D}$ - and the  $\alpha_{1A}$ -adrenoceptors, mediating peripheral vasoconstrictor actions. As noradrenaline has high potency at  $\alpha_{1D}$ -adrenoceptors, these receptors mediate the fastest response and seem to be targets for neurally released noradrenaline** especially to low frequency stimulation, with  $\alpha_{1A}$ -adrenoceptors being more important at high frequencies of stimulation. This is true in rodent vas deferens and may be true in vasopressor nerves controlling peripheral resistance and tissue blood flow. The  $\alpha_{1A}$ -adrenoceptor may act mainly through  $Ca^{2+}$  entry through L-type channels, whereas the  $\alpha_{1D}$ -adrenoceptor may act mainly through T-type channels and exhaustable  $Ca^{2+}$  stores.  $\alpha_1$ -Adrenoceptors may also act through non-G-protein linked second messenger systems. In many tissues, multiple subtypes of  $\alpha$ -adrenoceptor are present, and this may be regarded as the norm rather than exception, although one receptor subtype is usually predominant.